周三，摩根大通重申对礼来公司股票的"增持"评级，维持1,100.00美元的目标价。目前市值达8,180亿美元的这家制药巨头即将迎来其用于治疗2型糖尿病（T2D）和肥胖症的候选药物orforglipron的III期临床试验结果，预计分别将在2025年第 ...

礼来公司宣布收购Organovo旗下的FXR项目及其主打疗法FXR314，这是一款用于治疗溃疡性结肠炎等疾病的潜在“best-in-class”口服FXR小分子激动剂。Organovo已获得美国FDA的临床试验许可，正在进行2期试验，并计划将其应用于 ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

周三，伯恩斯坦分析师对礼来公司（NYSE:LLY）股票保持乐观态度，重申"优于大市"评级和1,100.00美元的目标价。这家市值达8,100亿美元的制药巨头目前交易价格接近52周高点，过去十二个月收入增长显著，达32%。根据 InvestingPro ...

Onvo Stock- Organovo's stock jumps 200% after Eli Lilly acquires its FXR program, including the promising IBD treatment ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

周二，礼来公司（Eli Lilly, NYSE: ...

全球制药巨头礼来近日宣布以4.5亿美元收购Organovo的FXR项目，这项交易不仅创下2025年开年最大生物技术并购案，更折射出药物研发领域正在经历范式转移。在传统新药研发成功率持续低迷的背景下（2024年Nature数据显示临床阶段药物失败率仍高达85%），Organovo凭借其革命性的3D生物打印技术平台，成功推动FXR314在溃疡性结肠炎等适应症上展现出best-in-class潜力。这场 ...

智通财经APP获悉，Organovo Holdings今日宣布，礼来(LLY.US)（Eli Lilly and ...

FXR314是一款潜在“best-in-class”的口服FXR小分子激动剂。目前，Organovo已获得美国FDA的临床试验许可，正在进行其主打疗法FXR314用于治疗溃疡性结肠炎（UC）的2期试验。公司通过其专有的3D人体组织模型，制定了针对FX ...

Matt Herren Announces His Exit from Bassmaster Elite Series Professional bass tournament angler, Matt Herren, has publicly ...